BTIG raises Cullinan Therapeutics price target to $40
BTIG raised its price target on Cullinan Therapeutics to $40.00 per share from $39.00, according to a Benzinga ratings action.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.